As part of an international clinical trial, Jacksonville-based Mayo Clinic in Florida has become the first U.S. site to target metastatic breast cancer with the radiopharmaceutical actinium-225.
The trial drug, which contains actinium-225, was developed to treat a subtype of gastroenteropancreatic neuroendocrine tumors. It is designed to “stick” to cancer cells as it delivers radiation without harming healthy cells, according to an Aug. 1 news release from the health system.
Mayo Clinic’s academic centers in Rochester, Minn., Phoenix and Jacksonville are participating in the trial, alongside 20 other sites across the U.S.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
